Drug Quality Focus On Asia, OTCs Supported By New US FDA Data
Executive Summary
OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.
You may also be interested in...
‘Temperature Abuse’ Heated US Drug Recalls To Record Level In FY2022, FDA Finds
Surveillance inspections nearly tripled as drug recalls reached highest level in five years, finds agency’s FY 2022 “state of pharmaceutical quality” report. Meanwhile, analysis points to lack of domestic API sources for many essential medicines.
‘Temperature Abuse’ Led Drug Recalls To New Heights In FY 2022, US FDA Finds
Surveillance inspections nearly tripled as drug recalls reached highest level in five years, finds agency’s FY 2022 “state of pharmaceutical quality” report. Meanwhile, analysis points to lack of domestic API sources for many essential medicines.
US FDA’s Machine Learning Analysis Suggests Where To Look For Manufacturing Site Quality Problems
XGBoost model sees site complexity contributes to quality risk, but misses device-related issues, says third FDA pharmaceutical quality report.